ImClone's Erbitux Improves Survival in Phase III Lung Cancer Trial
Posted on: Monday, 2 June 2008, 12:22 CDT
ImClone Systems and Bristol-Myers Squibb Company have reported positive results that show the addition of Erbitux to platinum-based chemotherapy significantly increased overall survival in the first-line treatment of patients with advanced non-small cell lung cancer, when compared with platinum-based chemotherapy alone.
This improvement in survival was observed across all histological subtypes, patient performance status, age groups, previous smoking history, and gender.
The pivotal, multinational study known as Flex was planned and conducted by Merck KGaA, Darmstadt, Germany, and enrolled more than 1,100 patients with Stage IIIB or Stage IV non-small cell lung cancer (NSCLC) who had not previously received chemotherapy.
Unlike previous pivotal studies of monoclonal antibodies in NSCLC, the Flex study enrolled patients with a broad range of performance capabilities and histological subtypes - reflective of physicians's everyday practice. For patients receiving Erbitux in combination with chemotherapy, median overall survival was prolonged by 1.2 months when compared to chemotherapy alone (11.3 months versus 10.1 months) for an hazard ratio of 0.871 [95% CI = 0.762-0.996], p=0.044.
Eric Rowinsky, executive vice president and chief medical officer of ImClone, said: "We look forward to submitting a supplemental biologics license application, or sBLA, later this year for Erbitux to be used in the first-line treatment of patients with non-small cell lung cancer on the basis of the Flex study results."
Source: Datamonitor
Related Articles
- Lung Cancer Oncogene Holds Key To Turning Off Cancer Stem Cells
- Researchers Identify Differences In Treatments, Outcomes Of Patients With Second Primary Lung Cancers Vs Those With One Primary Lung Cancer
- Scientists Develop Model That Could Help Identify Cancer Stem Cells
- Study Suggests Survival Benefit From Radioactive Microsphere Therapy in Patients With Colorectal Cancer Liver Metastases Who Have Failed Chemotherapy
- Exelixis Initiates Phase II Trial of XL880 in Patients With Gastric Cancer
- Data Show Geron's Telomerase Inhibitor Cancer Drug is Active Against Cancer Stem Cells From Multiple Myeloma Patients
- Avantogen and Innovate Oncology Announce Presentation of Clinical Data Demonstrating Extended Survival in Patients With Pancreatic Cancer Treated With RP101
- Aphton Reports Significant Activity of IGN101 in Patients With Epithelial Cancers
- Data Show Cyclosporine Inhalation Solution Improves Long-Term Survival in Lung-Transplant Patients
- Australian Cancer Technology Reports Doubling of Mean Survival Time in Patients With Pancreatic Cancer Using RP101 With Chemotherapy Treatment
 |
 |
User Comments (0)
RSS Feeds